Innovus Pharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference
SAN DIEGO–(BUSINESS WIRE)–Innovus
Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB Venture Market:
INNV), an emerging commercial stage pharmaceutical company that delivers
safe, innovative and effective over-the-counter medicine
and consumer care products to improve men and women’s health and
respiratory diseases, today announced today that Dr. Bassam Damaj,
President & Chief Executive Officer will present at the 2016 Rodman &
Renshaw 18th Annual Global Investment Conference, on Monday, September 12th.
Dr. Damaj will present an update on the Company’s growing revenues,
FlutiCare™, the launch of new products and plans to up-list to a higher
national exchange.
Event: Rodman & Renshaw 18th Annual Global Investment Conference
Date: Monday, September 12, 2016
Time: 3:00-3:25 PM EDT
Location: Louis Room, 4th Floor, Lotte New York Palace Hotel, 455
Madison Ave, New York, NY
Dr. Damaj and Robert Hoffman, Innovus Pharma’s in-coming Chief Financial
Officer, will be meeting with members of the investment community during
one-on-one meetings at the conference. The presentation will be
available for download on the Innovus Pharma web site (www.innovuspharma.com).
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC
and consumer products for men’s and women’s health and vitality. The
Company generates revenues from its lead
products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent,
(c) Zestra® for female arousal and (d) EjectDelay® for premature
ejaculation and has an additional five marketed products in this space,
including (e) Sensum+® for the indication of reduced penile sensitivity,
(for sales outside the U.S. only), (f) Zestra Glide®, (g) Vesele® for
promoting sexual and cognitive health, (i) Androferti® (in the US and
Canada) to support overall male reproductive health and sperm quality,
(j) BTH Vision Formula, (k) BTH Blood Sugar, (l) RecalMax™ for brain
health among others and eventually FlutiCare™ OTC for Allergic Rhinitis,
if its ANDA is approved by the U.S. FDA.
For more information, go to www.innovuspharma.com,
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com.
Innovus Pharma’s Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, “up-listing” to a higher national exchange, additional acquisitions,
commercial partnerships, and to achieve its other development, growth,
commercialization, financial and staffing objectives. Readers are
cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company’s most recent annual report on
Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from
the SEC’s website or without charge from the Company.
Contacts
Brokers and Analysts
Chesapeake Group
Kevin Holmes,
410-825-3930
info@chesapeakegp.com
